Thrivent Financial for Lutherans Grows Position in Haleon plc (NYSE:HLN)

Thrivent Financial for Lutherans lifted its stake in Haleon plc (NYSE:HLN) by 69.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 55,593 shares of the company’s stock after buying an additional 22,701 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Haleon were worth $588,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of HLN. B. Riley Wealth Advisors Inc. lifted its holdings in shares of Haleon by 23.2% in the first quarter. B. Riley Wealth Advisors Inc. now owns 29,324 shares of the company’s stock worth $246,000 after buying an additional 5,519 shares in the last quarter. Cetera Investment Advisers increased its position in Haleon by 106.3% in the first quarter. Cetera Investment Advisers now owns 233,788 shares of the company’s stock worth $1,985,000 after purchasing an additional 120,447 shares during the last quarter. Cetera Advisors LLC increased its position in Haleon by 524.3% in the first quarter. Cetera Advisors LLC now owns 81,991 shares of the company’s stock worth $696,000 after purchasing an additional 68,857 shares during the last quarter. GAMMA Investing LLC increased its position in Haleon by 64.6% in the second quarter. GAMMA Investing LLC now owns 10,051 shares of the company’s stock worth $83,000 after purchasing an additional 3,945 shares during the last quarter. Finally, Park Avenue Securities LLC increased its position in Haleon by 9.6% in the second quarter. Park Avenue Securities LLC now owns 127,667 shares of the company’s stock worth $1,055,000 after purchasing an additional 11,141 shares during the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Trading Down 0.2 %

HLN stock opened at $9.70 on Thursday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The stock has a market capitalization of $43.89 billion, a price-to-earnings ratio of 28.51, a price-to-earnings-growth ratio of 2.92 and a beta of 0.28. The firm’s fifty day simple moving average is $9.87 and its two-hundred day simple moving average is $9.46.

Analyst Upgrades and Downgrades

HLN has been the topic of several research reports. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley boosted their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.